[
  {
    "ts": null,
    "headline": "Gilead starts building manufacturing hub under $32 billion planned US investments",
    "summary": "Major U.S. drugmakers such as Eli Lilly, Johnson & Johnson, Merck and Bristol Myers Squibb have also announced big investments this year to boost domestic production, as tariffs threaten to raise costs and President Donald Trump pushes to bring more manufacturing to America.  Gilead's five-story, 180,000-square-foot facility \"is part of our vision for delivering next generation therapies,\" said CEO Daniel O'Day.",
    "url": "https://finnhub.io/api/news?id=c85d6da552d8c425c5693d0690907c65687198e3b08051290d49203e63a16732",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756919738,
      "headline": "Gilead starts building manufacturing hub under $32 billion planned US investments",
      "id": 136616970,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Major U.S. drugmakers such as Eli Lilly, Johnson & Johnson, Merck and Bristol Myers Squibb have also announced big investments this year to boost domestic production, as tariffs threaten to raise costs and President Donald Trump pushes to bring more manufacturing to America.  Gilead's five-story, 180,000-square-foot facility \"is part of our vision for delivering next generation therapies,\" said CEO Daniel O'Day.",
      "url": "https://finnhub.io/api/news?id=c85d6da552d8c425c5693d0690907c65687198e3b08051290d49203e63a16732"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy",
    "summary": "FOSTER CITY, Calif., September 03, 2025--Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters. This milestone marks continued momentum in Gilead’s multi-year strategy to drive growth and scientific leadership across virology, oncology, and inflammation, increasingly built on growing biologics capabilities. It is part of Gilead’s planned $32 bil",
    "url": "https://finnhub.io/api/news?id=777c08de0af1181d5e30d44b9ee43c0486ab5910a793689b74517c6e3e133e59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756917000,
      "headline": "Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy",
      "id": 136616971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., September 03, 2025--Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters. This milestone marks continued momentum in Gilead’s multi-year strategy to drive growth and scientific leadership across virology, oncology, and inflammation, increasingly built on growing biologics capabilities. It is part of Gilead’s planned $32 bil",
      "url": "https://finnhub.io/api/news?id=777c08de0af1181d5e30d44b9ee43c0486ab5910a793689b74517c6e3e133e59"
    }
  },
  {
    "ts": null,
    "headline": "The Play On Vir Biotechnology",
    "summary": "Vir Biotechnology trades at a significant discount to cash after a recent 65% drop, but faces rapid cash burn and slow pipeline progress. Learn more on VIR stock here.",
    "url": "https://finnhub.io/api/news?id=019f49dfa38e97e9c49663a28b667c82cad8d6d959202e3489490433f6af2ab3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756912498,
      "headline": "The Play On Vir Biotechnology",
      "id": 136631662,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184964962/image_184964962.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Vir Biotechnology trades at a significant discount to cash after a recent 65% drop, but faces rapid cash burn and slow pipeline progress. Learn more on VIR stock here.",
      "url": "https://finnhub.io/api/news?id=019f49dfa38e97e9c49663a28b667c82cad8d6d959202e3489490433f6af2ab3"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Presents At Cantor Global Healthcare Conference 2025 Transcript",
    "summary": "Get the latest on Gilead Sciencesâ diverse R&D pipeline, HIV innovations, oncology advances,",
    "url": "https://finnhub.io/api/news?id=02ebcaea1e22535096faa2c8da4eeb85851141e5636dea008a121ed8583dfc2d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756909844,
      "headline": "Gilead Sciences, Inc. (GILD) Presents At Cantor Global Healthcare Conference 2025 Transcript",
      "id": 136630998,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Get the latest on Gilead Sciencesâ diverse R&D pipeline, HIV innovations, oncology advances,",
      "url": "https://finnhub.io/api/news?id=02ebcaea1e22535096faa2c8da4eeb85851141e5636dea008a121ed8583dfc2d"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock to Consider Right Now and 2 We Question",
    "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 9.7%.",
    "url": "https://finnhub.io/api/news?id=87486f971bf218d9ef2e3bdb7d2f1fe6edaa5fe3cab1ac2f8fbf9503430cbe8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756877812,
      "headline": "1 Healthcare Stock to Consider Right Now and 2 We Question",
      "id": 136613203,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 9.7%.",
      "url": "https://finnhub.io/api/news?id=87486f971bf218d9ef2e3bdb7d2f1fe6edaa5fe3cab1ac2f8fbf9503430cbe8b"
    }
  }
]